Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of HF158K1 in Participants With HER-2 Expressing Advanced Solid Tumors

NCT05861895 is registered in ClinicalTrials.gov with HighField Biopharmaceuticals Corporation as lead sponsor.

NCT NCT05861895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05861895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of HF158K1 in Participants With HER-2 Expressing Advanced Solid Tumors
Lead sponsor
HighField Biopharmaceuticals Corporation
Phase
Phase 1
Overall status
Recruiting
Start date
December 12, 2023
Completion date
December 23, 2027
Enrollment
84 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, adult